N. Bahlis

J. Storek, N. Bahlis, N. Bahlis, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2021, The Lancet. Oncology.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Bingshu E. Chen, T. Reiman, D. Reece, 2016, Blood.

N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells

L. Boise, Kelvin P Lee, S. Gerson, 2005 .

N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.

L. Boise, Kelvin P Lee, S. Gerson, 2005, Leukemia and Lymphoma.

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

S. Lonial, S. Iida, T. Plesner, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reovirus as a successful ex vivo purging modality for multiple myeloma

P. Neri, C. Thirukkumaran, J. Luider, 2014, Bone Marrow Transplantation.

Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

P. Neri, C. Thirukkumaran, J. Luider, 2012, Clinical Cancer Research.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

M. Dimopoulos, M. Mohty, J. Cavenagh, 2018, Blood.

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma

D. Siegel, W. Pierceall, P. Neri, 2020, Clinical Cancer Research.

Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals

L. Carlson, Kelvin P Lee, N. Bahlis, 2004, Cancer Immunology, Immunotherapy.

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

J. Laubach, S. Iida, H. Nahi, 2022, Haematologica.

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2022, Blood.

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

S. Tuchman, N. Callander, G. Schiller, 2021, British Journal of Cancer.

Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.

P. Vyas, P. Dhiman, P. Neri, 2020, Blood.

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius

S. Lonial, P. Richardson, A. Belch, 2017 .

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant

P. Neri, J. Luider, P. Duggan, 2016, Leukemia & lymphoma.

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

J. Shah, D. Reece, P. Neri, 2018, Blood.

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

M. Sebag, R. Kotb, M. Lalancette, 2016 .

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

G. Tricot, D. Demarini, A. Roberts, 2009, Blood.

Clinical ef ﬁ cacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

S. Lonial, P. Richardson, T. Plesner, 2016 .

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center.

P. Neri, C. Chambers, P. Duggan, 2021, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic

T. Dunne, P. Neri, P. Duggan, 2021, Leukemia & lymphoma.

The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease

P. Richardson, A. Vangsted, K. Ramasamy, 2022, Expert review of proteomics.

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Preventing and treating chronic disorders using the modified vaccination technique.

R. Graeff, R. Lafrenière, N. Bahlis, 2009, Frontiers in bioscience.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

S. Jagannath, A. Jakubowiak, S. Lonial, 2009 .

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

M. Horowitz, K. Ballen, C. Bredeson, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.

P. Neri, P. Duggan, V. Jimenez-Zepeda, 2016, Clinical lymphoma, myeloma & leukemia.

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, American journal of hematology.

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

S. Tuchman, N. Callander, G. Schiller, 2020, EJHaem.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.

S. Lonial, J. Laubach, P. Richardson, 2020, The Lancet. Haematology.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

H. Goldschmidt, M. Dimopoulos, A. Oriol, 2015, Haematologica.

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

H. Goldschmidt, O. Decaux, M. Mohty, 2022, Leukemia.

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

M. Dimopoulos, P. Moreau, J. Kaufman, 2019, Blood.

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

D. Siegel, W. Pierceall, S. Srinivasan, 2019, British journal of haematology.

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

J. Storek, P. Duggan, N. Bahlis, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Teclistamab in Relapsed or Refractory Multiple Myeloma.

A. Krishnan, J. Goldberg, H. Nahi, 2022, The New England journal of medicine.

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

S. Iida, H. Nahi, Kihyun Kim, 2021, Annals of Hematology.

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

J. Laubach, S. Iida, H. Nahi, 2020, The Lancet. Haematology.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

H. Goldschmidt, U. Mellqvist, M. Dimopoulos, 2021, The Lancet. Oncology.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, S. Lonial, 2022, The Lancet. Haematology.

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

D. Siegel, W. Pierceall, D. Reece, 2020, Leukemia.

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

S. Lonial, S. Iida, T. Plesner, 2018, Blood.

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

S. Trudel, T. Reiman, A. Belch, 2010 .

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

A. Jakubowiak, R. Vij, A. Belch, 2009 .

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, S. Lonial, 2012, Clinical lymphoma, myeloma & leukemia.

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

L. Boise, Kelvin P Lee, J. Neil, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Vaccination Technique to Combat Presently Untreatable Chronic Ailments

R. Lafrenière, N. Bahlis, A. Barabas, 2008 .

IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance

C. Fontanillo, A. Klippel, P. Neri, 2014 .

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2018, Blood.

Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.

L. Boise, Kelvin P Lee, N. Krett, 2003, Molecular cancer therapeutics.

myeloma cells induced cytotoxicity in multiple - Ascorbic acid enhances arsenic trioxide

W. Dalton, L. Boise, N. Bahlis, 2013 .

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

A. Magliocco, F. Naveed, J. Storek, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

W. Irish, J. Storek, P. Duggan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

W. Dalton, L. Boise, N. Bahlis, 2001, Blood.

Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma

R. Kloiber, A. Mansoor, P. Duggan, 2014, Leukemia & lymphoma.

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial

Lili Liu, P. Fu, S. Remick, 2007, Cancer Chemotherapy and Pharmacology.

Treatment of Relapsed/Refractory Multiple Myeloma.

P. Richardson, P. Neri, N. Bahlis, 2016, Cancer treatment and research.

Darwinian evolution and tiding clones in multiple myeloma.

N. Bahlis, 2012, Blood.

Profiling Chromatin Accessibility at Single-cell Resolution

Ansuman T. Satpathy, Hongkai Ji, J. A. Stratton, 2021, Genom. Proteom. Bioinform..

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, P. Richardson, 2016, The New England journal of medicine.

Panobinostat for the treatment of multiple myeloma

S. Lonial, P. Neri, Sagar Lonial, 2012, Expert opinion on investigational drugs.

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).

Mir Ishruna Muniyat, J. MacCallum, P. Neri, 2019, Journal of medicinal chemistry.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A. Palumbo, A. Hui, P. Ganly, 2016, The New England journal of medicine.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

H. Goldschmidt, M. Dimopoulos, A. Oriol, 2015, Haematologica.

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

P. Tassone, P. Neri, L. Boise, 2011, Blood.

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2020 .

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

S. Trudel, M. Brundage, T. Reiman, 2013, Blood.

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

T. Reiman, Sunita Ghosh, L. Pilarski, 2011, Leukemia research.

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.

P. Vyas, P. Dhiman, P. Neri, 2021, Blood.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

S. Lonial, P. Tassone, P. Neri, 2010, Blood.

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

B. Andersson, F. Naveed, J. Storek, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation

M. Parkins, N. Bahlis, D. Stewart, 2006, Bone Marrow Transplantation.

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

J. Storek, P. Duggan, N. Bahlis, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG

J. Storek, P. Duggan, N. Bahlis, 2011, Bone Marrow Transplantation.

The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience

P. Neri, P. Duggan, J. Tay, 2020, European journal of haematology.

Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.

Nizar Bahlis, Peter Duggan, J. Storek, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

L. Kmet, J. Storek, N. Bahlis, 2006 .

A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred

P. Hawkins, N. Rendell, D. Rowczenio, 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A. Jakubowiak, A. Krishnan, S. Lonial, 2016, The Lancet.

Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight

P. Neri, P. Duggan, V. Jimenez-Zepeda, 2016, Leukemia & lymphoma.

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

D. Siegel, D. Reece, A. Agarwal, 2020 .

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.

H. Goldschmidt, K. Rippe, R. Sankowski, 2023, Cancer cell.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2018, Haematologica.

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

D. Siegel, D. Reece, G. Schiller, 2018 .

Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile

M. Trotter, A. Klippel, P. Neri, 2015 .

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2021 .

CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2014 .

Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

D. Auclair, J. Keats, S. Lonial, 2016 .

A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.

L. Carlson, P. Duggan, N. Bahlis, 2011, Clinical lymphoma, myeloma & leukemia.

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A. Jakubowiak, S. Trudel, A. Lesokhin, 2020 .

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

G. Vanhoof, H. Ceulemans, T. Plesner, 2020, Leukemia.

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

P. Neri, P. Duggan, V. Jimenez-Zepeda, 2020 .

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

M. Dimopoulos, J. Cavenagh, A. Dispenzieri, 2013 .

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA.

M. Dimopoulos, P. Sonneveld, N. Munshi, 2021, Blood.

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

J. Shah, M. Dimopoulos, S. Jagannath, 2021, American journal of hematology.

S. Leyvraz, Sung-Soo Yoon, C. Langer, 2015, Haematologica.

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

M. Dimopoulos, P. Sonneveld, Honghui Zhou, 2020, Clinical and translational science.

Thalidomide‐prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10

A. Belch, D. Reece, M. Kovacs, 2015, British journal of haematology.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

H. Goldschmidt, M. Dimopoulos, P. Richardson, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world outcomes with cumulative bortezomib dose and efficacy in the treatment of transplant-ineligible multiple myeloma with cyclophosphamide, bortezomib, and dexamethasone

P. Neri, P. Duggan, J. Tay, 2022, Clinical Lymphoma Myeloma and Leukemia.

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

S. Srinivasan, A. Dispenzieri, A. Belch, 2020, Cancer medicine.

Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution

P. Neri, P. Duggan, J. Tay, 2018, Leukemia & lymphoma.

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

O. Decaux, H. Nahi, S. Basu, 2017, Leukemia.

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, British journal of haematology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

N. Bahlis, D. Stewart, J. Russell, 2006, Blood.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

P. Richardson, Shaji K. Kumar, D. Reece, 2009, British journal of haematology.

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

S. Iida, H. Nahi, V. De Stefano, 2020, Journal of Cancer Research and Clinical Oncology.

Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.

L. Kmet, A. Mansoor, N. Bahlis, 2006 .

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

J. Laubach, S. Iida, H. Nahi, 2019, Journal of Clinical Oncology.

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

M. Dimopoulos, J. Miguel, S. Iida, 2019, Journal of Clinical Oncology.

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

S. Lonial, P. Richardson, Shaji K. Kumar, 2021, Blood.

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

D. Siegel, D. Reece, A. Agarwal, 2018, Blood.

High-Risk Cytogenetics Multiple Myeloma: Impact of Consolidation and Maintenance

P. Neri, P. Duggan, J. Tay, 2016 .

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma

S. Lonial, P. Neri, N. Bahlis, 2016, Clinical Cancer Research.

Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program

P. Neri, P. Duggan, J. Tay, 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.

P. Neri, J. Luider, P. Duggan, 2019, Clinical lymphoma, myeloma & leukemia.

N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution

P. Neri, P. Duggan, J. Tay, 2021, Annals of Hematology.

Shaji K. Kumar, T. Plesner, R. Orlowski, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

M. Dimopoulos, S. Trudel, P. Richardson, 2021, Blood.

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

S. Lonial, S. Trudel, P. Richardson, 2020 .

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

S. Lonial, S. Trudel, P. Richardson, 2020 .

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

R. Vij, N. Callander, P. Moreau, 2023, The New England journal of medicine.

pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation

A. Mansoor, N. Bahlis, D. Stewart, 2009, Leukemia & lymphoma.

Pinning down myeloma with Pim2 inhibitors!

P. Neri, N. Bahlis, 2013, Blood.

Then Cellot Et Al

N. Bahlis, 2022 .

Title: UPFRONT DOUBLE HIGH DOSE CHEMOTHERAPY WITH DICEP FOLLOWED BY BEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS AGGRESSIVE NON-HODGKIN'S LYMPHOMA Running Head: UPFRONT DICEP-BEAM/ASCT FOR POOR PROGNOSIS NHL

T. Baker, N. Bahlis, D. Stewart, 2006 .

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

A. Jakubowiak, S. Trudel, M. Tomasson, 2021 .

Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center

N. Fine, P. Neri, P. Duggan, 2021, Indian Journal of Hematology and Blood Transfusion.

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

J. Laubach, S. Iida, H. Nahi, 2019, Blood.

CNV Radar: an improved method for somatic copy number alteration characterization in oncology

Angela Dispenzieri, Christopher Chiu, Faith Davies, 2020, BMC Bioinformatics.

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

A. Jakubowiak, S. Trudel, M. Tomasson, 2021, Blood.

An Automated and Quantitative Protein Expression-Based Classification System to Identify High Risk Multiple Myeloma Patients

P. Neri, A. Magliocco, A. Klimowicz, 2008 .

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

P. Ganly, J. Laubach, P. Richardson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients.

S. Lonial, P. Richardson, Shaji K. Kumar, 2021, Blood.

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents

J. Licht, J. Phillip, D. Wirtz, 2016, Oncogene.

Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center

P. Neri, P. Duggan, J. Tay, 2019, Leukemia & lymphoma.

Venetoclax ex vivo functional profiling predicts improved progression-free survival

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Blood Cancer Journal.

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

M. Dimopoulos, A. Belch, D. Reece, 2015 .

Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2017 .

Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2021, Blood.

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

J. Keats, S. Lonial, A. Tron, 2018, Blood.

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

J. Keats, P. Neri, P. Duggan, 2012 .

H. Goldschmidt, M. Dimopoulos, T. Plesner, 2021, British journal of haematology.

Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report

N. Bahlis, S. Peters, Natalya Patrick, 2023, The Neurohospitalist.

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

P. Neri, P. Duggan, J. Tay, 2018, Blood.

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

P. Neri, P. Duggan, J. Tay, 2018, Blood.

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

D. Siegel, W. Pierceall, D. Reece, 2018, Blood.

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

P. Neri, L. Boise, P. Duggan, 2017 .

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

P. Neri, P. Duggan, J. Tay, 2017 .

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

D. Reece, A. Agarwal, G. Schiller, 2017 .

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

S. Lonial, G. Vanhoof, T. Plesner, 2017 .

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, S. Trudel, M. Tomasson, 2022, Blood.

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

Reovirus modulates autophagy during oncolysis of multiple myeloma

P. Neri, C. Thirukkumaran, J. Luider, 2013, Autophagy.

Selinexor for the treatment of patients with previously treated multiple myeloma

S. Jagannath, S. Lonial, P. Richardson, 2021, Expert review of hematology.

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

S. Tuchman, N. Callander, M. Leiba, 2021, Blood.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.

P. Neri, N. Bahlis, 2012, Current cancer drug targets.

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma

F. Malavasi, A. Babich, N. V. D. van de Donk, 2021, Haematologica.

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

D. Horsman, M. Eliasziw, D. Reece, 2007 .

DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX)

H. Goldschmidt, M. Dimopoulos, P. Richardson, 2017 .

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

P. Neri, F. Maura, O. Landgren, 2022, Blood.

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).

A. Krishnan, S. Singhal, A. Belch, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

D. Esseltine, P. Ganly, N. Munshi, 2016 .

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

A. Palumbo, A. Hui, P. Ganly, 2015 .

A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)

D. Doval, A. Chanan-Khan, A. Belch, 2010 .

Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer

M. Lupien, J. Cairncross, M. Gallo, 2020, Science advances.

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

S. Tuchman, N. Callander, G. Schiller, 2022, Blood.

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

S. Tuchman, N. Callander, G. Schiller, 2021, EJHaem.

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

S. Tuchman, N. Callander, G. Schiller, 2021, Blood.

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

M. Dimopoulos, S. Jagannath, Xiwen Ma, 2021, American journal of hematology.

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

J. Shah, S. Tuchman, N. Callander, 2020 .

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2021, Blood.

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

S. Jagannath, S. Lonial, P. Richardson, 2015 .

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

M. Dimopoulos, S. Iida, A. Oriol, 2020, Blood Cancer Journal.

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

J. Shah, S. Tuchman, N. Callander, 2020 .

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).

M. Tomasson, S. Iida, M. Mohty, 2022, Journal of Clinical Oncology.

Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2013 .

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2022, Blood.

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

R. Fonseca, A. Krishnan, S. Trudel, 2022, Blood.

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

D. Esseltine, P. Ganly, J. Miguel, 2016 .

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2019, Blood.

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

D. Sullivan, G. Schiller, M. Sebag, 2018, Blood.

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

M. Tomasson, S. Iida, M. Mohty, 2022, Blood.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

J. Goldberg, P. Moreau, R. Verona, 2022, Blood.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

H. Lazarus, N. Bahlis, N. Bahlis, 2006, Bone Marrow Transplantation.

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

M. Dimopoulos, A. Jakubowiak, Shaji K. Kumar, 2020 .

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

A. Belch, P. Neri, A. Klimowicz, 2012 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

A. Oza, T. Pugh, S. Trudel, 2016 .

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

C. Touzeau, T. Facon, J. Harousseau, 2023, Clinical Hematology International.

Copy-scAT: An R package for detection of large-scale and focal copy number alterations in single-cell chromatin accessibility datasets

M. Gallo, Sorana A. Morrissy, P. Neri, 2020, bioRxiv.

Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2013 .

Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis

P. Neri, P. Duggan, J. Tay, 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics

T. Reiman, L. Pilarski, A. Belch, 2011, Leukemia & lymphoma.

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

A. Krishnan, A. Oriol, P. Moreau, 2023, Journal of Clinical Oncology.

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

M. Tomasson, S. Iida, M. Mohty, 2023, Journal of Clinical Oncology.

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

H. Goldschmidt, D. Reece, A. Oriol, 2023, Journal of Clinical Oncology.

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

M. Dimopoulos, P. Moreau, M. Leiba, 2018, Blood.

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.

M. Dimopoulos, P. Richardson, R. Hájek, 2020 .